Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy


Author index

Page Path
HOME > Browse Articles > Author index
Field F. Willingham 3 Articles
Epidemiology of early esophageal adenocarcinoma
Thuy-Van P. Hang, Zachary Spiritos, Anthony M. Gamboa, Zhengjia Chen, Seth Force, Vaishali Patel, Saurabh Chawla, Steven Keilin, Nabil F. Saba, Bassel El-Rayes, Qiang Cai, Field F. Willingham
Clin Endosc 2022;55(3):372-380.   Published online February 11, 2022
AbstractAbstract PDFPubReaderePub
/Aims: Endoscopic resection has become the preferred treatment approach for select early esophageal adenocarcinoma (EAC); however, the epidemiology of early stage disease has not been well defined.
Surveillance Epidemiology and End Results (SEER) data were analyzed to determine age-adjusted incidence rates among major epithelial carcinomas, including EAC, from 1973 to 2017. The percent change in incidence over time was compared according to tumor subtype. Early T-stage, node-negative EAC without metastasis was examined from 2004 to 2017 when precise T-stage data were available.
The percent change in annual incidence from 1973 to 2017 was 767% for EAC. Joinpoint analysis showed that the average annual percent change in EAC from 1973 to 2017 was 5.11% (95% confidence interval, 4.66%–5.56%). The annual percent change appeared to plateau between 2004 and 2017; however, early EAC decreased from 2010 to 2017, with an annual percent change of -5.78%.
There has been a 7-fold increase in the incidence of EAC, which was significantly greater than that of the other major epithelial malignancies examined. More recently, the incidence of early EAC has been decreasing. Approximately one in five patients has node negative, potentially resectable early stage disease.


Citations to this article as recorded by  
  • Concise Commentary: It’s All Downhill from Here—How Diagnostic and Therapeutic Advances May Decrease the Incidence Rates of Gastroesophageal Junction and Esophageal Adenocarcinoma
    Anthony Gamboa, Rishi Naik
    Digestive Diseases and Sciences.2024; 69(1): 254.     CrossRef
  • Descriptive Epidemiology of Early-Onset Gastrointestinal Cancers in Iran, 2014-2018
    Mohammad Sadra Gholami Chahkand, Fatemeh Esmaeilpour Moallem, Fatemeh Ghasemi-Kebria, Reza Malekzadeh, Gholamreza Roshandel, Mohammad Taher
    Middle East Journal of Digestive Diseases.2024; 16(1): 28.     CrossRef
  • Epidemiologie der Adenokarzinome des Ösophagus und des ösophagogastralen Übergangs
    Sabine Luttmann, Andrea Eberle, Joachim Hübner
    Die Onkologie.2023; 29(6): 470.     CrossRef
  • Evaluation of Esophageal Dysphagia in Elderly Patients
    Khanh Hoang Nicholas Le, Eric E. Low, Rena Yadlapati
    Current Gastroenterology Reports.2023; 25(7): 146.     CrossRef
  • Histology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study
    Tieying Hou, Zhaohai Yang, Qingzhao Zhang, Xuchen Zhang, Xiaoyan Liao, Jingmei Lin
    International Journal of Surgical Pathology.2023;[Epub]     CrossRef
  • Molecular Biology and Clinical Management of Esophageal Adenocarcinoma
    Shulin Li, Sanne Johanna Maria Hoefnagel, Kausilia Krishnawatie Krishnadath
    Cancers.2023; 15(22): 5410.     CrossRef
  • Progress in Clinical Management of Esophago-Jejunal Anastomotic Fistula with Total Gastrectomy for Adenocarcinoma of the Esophagogastric Junction
    天伟 赖
    Advances in Clinical Medicine.2023; 13(11): 17210.     CrossRef
  • Cranberry Proanthocyanidins Mitigate Reflux-Induced Transporter Dysregulation in an Esophageal Adenocarcinoma Model
    Yun Zhang, Katherine M. Weh, Bridget A. Tripp, Jennifer L. Clarke, Connor L. Howard, Shruthi Sunilkumar, Amy B. Howell, Laura A. Kresty
    Pharmaceuticals.2023; 16(12): 1697.     CrossRef
  • Lessons learned in clinical epidemiology of esophageal adenocarcinoma
    Hye Kyung Jung
    Clinical Endoscopy.2022; 55(3): 365.     CrossRef
  • 4,788 View
  • 268 Download
  • 5 Web of Science
  • 9 Crossref
Close layer
Practice Patterns and Use of Endoscopic Retrograde Cholangiopancreatography in the Management of Recurrent Acute Pancreatitis
Jonathan B. Reichstein, Vaishali Patel, Parit Mekaroonkamol, Sunil Dacha, Steven A. Keilin, Qiang Cai, Field F. Willingham
Clin Endosc 2020;53(1):73-81.   Published online July 5, 2019
AbstractAbstract PDFPubReaderePub
/Aims: There are conflicting opinions regarding the management of recurrent acute pancreatitis (RAP). While some physicians recommend endoscopic retrograde cholangiopancreatography (ERCP) in this setting, others consider it to be contraindicated in patients with RAP. The aim of this study was to assess the practice patterns and clinical features influencing the management of RAP in the US.
An anonymous 35-question survey instrument was developed and refined through multiple iterations, and its use was approved by our Institutional Review Board. The survey was distributed via email to 408 gastroenterologists to assess the practice patterns in the management of RAP in multiple clinical scenarios.
The survey was completed by 65 participants representing 36 of the top academic/tertiary care centers across the country. Approximately 90.8% of the participants indicated that they might offer or recommend ERCP in the management of RAP. Multinomial logistic regression analysis revealed that ductal dilatation and presence of symptoms were the most predictive variables (p<0.001) for offering ERCP.
A preponderance of the respondents would consider ERCP among patients with RAP presenting to tertiary care centers in the US. Ductal dilatation, presence of symptoms, and pancreas divisum significantly increased the likelihood of a recommendation for ERCP


Citations to this article as recorded by  
  • Controversies in ERCP: Technical aspects
    ChristophF Dietrich, NoorL Bekkali, Sean Burmeister, Yi Dong, SimonM Everett, Michael Hocke, Andre Ignee, Wei On, Srisha Hebbar, Kofi Oppong, Siyu Sun, Christian Jenssen, Barbara Braden
    Endoscopic Ultrasound.2022; 11(1): 27.     CrossRef
  • Controversies in ERCP: Indications and preparation
    ChristophF Dietrich, NoorL Bekkali, Sean Burmeister, Yi Dong, SimonM Everett, Michael Hocke, Andre Ignee, Wei On, Srisha Hebbar, Kofi Oppong, Siyu Sun, Christian Jenssen, Barbara Braden
    Endoscopic Ultrasound.2022; 11(3): 186.     CrossRef
  • Biliary hitch and ride technique for blind pancreatic duct cannulation
    Juan J. Vila, Juan Carrascosa, Ignacio Fernández-Urién, Paul Yeaton, Gonzalo González, Leire Aburruza, José Manuel Zozaya
    Endoscopy.2021; 53(01): E29.     CrossRef
  • Endoscopic Retrograde Cholangiopancreatography in Recurrent Acute Pancreatitis: Determining the Optimal Subgroup of Patients in Whom the Procedure is Beneficial
    Tae Yoon Lee, Takuji Iwashita
    Clinical Endoscopy.2020; 53(1): 5.     CrossRef
  • 4,733 View
  • 175 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Long -Term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation
Zachary Spiritos, Parit Mekaroonkamol, Bassel F. El- Rayes, Seth D. Force, Steven A. Keilin, Qiang Cai, Field F. Willingham
Clin Endosc 2017;50(5):491-494.   Published online April 24, 2017
AbstractAbstract PDFPubReaderePub
Esophageal cancer has a poor overall prognosis and is frequently diagnosed at a late stage. Conventional treatment for metastatic esophageal cancer involves chemotherapy and radiation. Local disease control plays a significant role in improving survival. Endoscopic spray cryotherapy is a novel modality that involves freezing and thawing to produce local ablation of malignant tissue via ischemic mechanisms. Spray cryotherapy has been shown to be effective, particularly for early T-stage, superficial esophageal adenocarcinomas. We present the case of a 72-year-old-male with locally recurrent stage IV esophageal adenocarcinoma and long-term survival of 7 years to date, with concurrent chemoradiation and serial cryoablation. He remains asymptomatic and continues to undergo chemotherapy and sequential cryoablation. The findings highlight the long-term safety and efficacy of cryotherapy in combination with chemoradiation, and suggest that cryoablation may have an additive role in the treatment of advanced stage esophageal adenocarcinoma.


Citations to this article as recorded by  
  • Endoscopic Palliative Therapies for Esophageal Cancer
    Youssef Y. Soliman, Madappa Kundranda, Toufic Kachaamy
    Gastrointestinal Endoscopy Clinics of North America.2024; 34(1): 91.     CrossRef
  • Role of oesophageal balloon cryoablation in combination with personalised immunotherapy to achieve luminal control in metastatic oesophageal cancer: a case report
    Benjamin Charles Norton, Apostolis Papaefthymiou, Andrea Telese, Margaret Duku, Imran Chaudhry, Alberto Murino, Gavin Johnson, Charles Murray, Rehan Haidry
    Frontline Gastroenterology.2024; 15(4): 336.     CrossRef
  • Cryoballoon ablation as salvage therapy after nonradical resection of a high-risk T1b esophageal adenocarcinoma: a case report
    Charlotte N. Frederiks, Jolanda M.W. van de Water, Gati Ebrahimi, Bas L.A.M. Weusten
    European Journal of Gastroenterology & Hepatology.2022; 34(3): 354.     CrossRef
  • Surgery to the primary tumor is associated with improved survival of patients with metastatic esophageal cancer: propensity score-matched analyses of a large retrospective cohort
    Rui Zhang, Jiahua Zou, Ping Li, Qin Li, Yunfeng Qiao, Jianglong Han, Kejie Huang, Peng Ruan, Huiqing Lin, Qibin Song, Zhenming Fu
    Diseases of the Esophagus.2019;[Epub]     CrossRef
  • 6,907 View
  • 129 Download
  • 3 Web of Science
  • 4 Crossref
Close layer

Clin Endosc : Clinical Endoscopy Twitter Facebook
Close layer